Influence of electronic cigarette liquid flavors and nicotine concentration on subjective measures of abuse liability in young adult cigarette smokers.

Plain-language guide to PMID 31401532 (2019): double-blind controlled clinical trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 31401532
Journal: Drug and alcohol dependence
Year: 2019
Study type: Controlled Clinical Trial
Authors: Cobb CO et al. (10 authors)
DOI: 10.1016/j.drugalcdep.2019.05.024

What This Study Did, in Plain Language

What Was Tested

This controlled clinical trial looks at Therapeutic nicotine (patch, non-peptide).

This study aimed to evaluate the extent to which ECIG liquid flavor and nicotine concentration influenced subjective measures of abuse liability among young adult cigarette (cig) smokers.

Why It Was Studied

A rapidly evolving tobacco marketplace highlights the timeliness of the FDA's authority to regulate tobacco, specifically the role that flavorings in nicotine-containing electronic cigarette (ECIG) liquids have on public health.

Who Took Part

The age groups tagged for this paper are teenagers and young adults, both men and women.

Young adult (18-21 y.o.) smokers (M = 10.1 cig/day, no regular ECIG use history) completed 7 Latin-square ordered conditions each preceded by 12 h. nicotine/tobacco abstinence.

How the Study Was Run

The researchers set it up as a double-blind study.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Products were administered in two 10-puff bouts in each condition.

Heart rate/blood pressure (HR/BP) and tobacco/nicotine abstinence symptoms, nicotine/general drug effects, and acceptability measures were assessed repeatedly throughout sessions.

Mixed linear models were followed-up with Tukey's HSD t-tests.

What Was Measured

PubMed files the paper under topics including Electronic Nicotine Delivery Systems, Flavoring Agents, Heart Rate, Menthol, Nicotine, Smokers and Taste.

The authors tagged it with the keywords Abuse liability, Cigarette smoking, Electronic cigarette, Subjective and Young adult.

What This Means in Plain Language

The paper is a double-blind study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Drug and alcohol dependence), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.